Stockscreener 앱 받기
672.32
0.02%
0.1682
전일 마감가:
$672.15
열려 있는:
$672.55
하루 거래량:
201.99K
Relative Volume:
0.21
시가총액:
$70.47B
수익:
$14.92B
순이익/손실:
$4.42B
주가수익비율:
16.38
EPS:
41.0422
순현금흐름:
$3.79B
1주 성능:
+2.47%
1개월 성능:
+10.23%
6개월 성능:
-10.28%
1년 성능:
+23.24%
1일 변동 폭
$666.87
$678.67
1주일 범위
$648.66
$691.13
52주 변동 폭
$541.00
$821.11
리제네론 파마슈티컬스 Stock (REGN) Company Profile
명칭
Regeneron Pharmaceuticals Inc
전화
(914) 847-7000
주소
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
672.21 | 70.47B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
479.71 | 121.95B | 12.34B | 4.34B | 3.71B | 16.87 |
ARGX
Argen X Se Adr
|
870.73 | 52.94B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
183.04 | 38.35B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
274.59 | 36.40B | 4.29B | 577.22M | 641.34M | 4.2086 |
리제네론 파마슈티컬스 Stock (REGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-31 | 재개 | Piper Sandler | Overweight |
| 2026-03-06 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2025-12-03 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | 개시 | HSBC Securities | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-14 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-06-30 | 다운그레이드 | Argus | Buy → Hold |
| 2025-05-30 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-05 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-09-24 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 개시 | Bernstein | Outperform |
| 2024-01-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-03 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 재확인 | Oppenheimer | Perform |
| 2023-06-28 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-23 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2023-01-20 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-10-26 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-09-09 | 업그레이드 | Jefferies | Underperform → Hold |
| 2022-09-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 개시 | Jefferies | Underperform |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-01-03 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-12-07 | 재개 | Cowen | Market Perform |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 재개 | BMO Capital Markets | Outperform |
| 2021-11-05 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 개시 | H.C. Wainwright | Buy |
| 2021-01-25 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2021-01-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-10-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2020-07-09 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-05-26 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-04-17 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 개시 | The Benchmark Company | Hold |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-02-27 | 개시 | Barclays | Overweight |
| 2020-02-26 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-11 | 업그레이드 | Argus | Hold → Buy |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-16 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-12-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 개시 | SunTrust | Hold |
| 2019-11-07 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
모두보기
리제네론 파마슈티컬스 주식(REGN)의 최신 뉴스
REGN Maintained by Guggenheim -- Price Target Raised to $1000 - GuruFocus
REGN Investors Have Opportunity to Lead Regeneron - GlobeNewswire
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026REGN - PR Newswire
Regeneron stock holds its ground as sales and earnings stay strong - Ad-hoc-news.de
Telix Pharmaceuticals (TLX) hits US$247M Q2, inks Regeneron deal - Stock Titan
Telix Pharmaceuticals Limited and Regeneron Pharmaceuticals, Inc. Enter into Strategic Collaboration to Jointly Develop and Commercialize Next-Generation Radiopharmaceutical Therapies and Advance Multiple Novel Oncology Programs - marketscreener.com
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - GlobeNewswire Inc.
REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - lincolnjournal.com
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff - GlobeNewswire
Albany's construction sector signals growth from Regeneron's $2B expansion to rising contractor billings - MarketScale
Regeneron stock holds after 2025 revenue and earnings growth - Ad-hoc-news.de
Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating - marketscreener.com
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
Regeneron Pharmaceuticals (REGN) Jefferies Global Healthcare Conference Summary - Quartr
Regeneron stock trades steady as Eylea and Dupixent growth support earnings - ad-hoc-news.de
Regeneron Pharmaceuticals, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – REGN - mykxlg.com
REGN SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026 - marketscreener.com
Regeneron stock trades near recent highs as Dupixent growth and pipeline updates support valuation - ad-hoc-news.de
Regeneron's Gene Therapy For Genetic Hearing Loss Gets Accelerated FDA Nod — Drug Pricing Deal With White House To Be Announced Today - Stocktwits
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Regeneron (REGN) Stock Looks Discounted As It Holds A 24% Gain - simplywall.st
REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron - GlobeNewswire
Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In? - Yahoo Finance
REGN Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. - PR Newswire
Regeneron stock trades steady as Eylea and Dupixent revenue support earnings trajectory - ad-hoc-news.de
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
Regeneron Investor Sues Over Cancer Drug Trial Miss, Stock Drops - Bloomberg Law News
Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit - Business Wire
Price-Driven Insight from (REGN) for Rule-Based Strategy - Stock Traders Daily
Regeneron Pharmaceuticals (Ondo Tokenized) price today, REGNON to USD live price, marketcap and chart - CoinDesk
Regeneron Pharmaceuticals (REGN) Stumbled In A Trial Setback, Is The Stock Still Cheap? - simplywall.st
Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilu - GuruFocus
Regeneron (REGN) Receives FDA Orphan Drug Designation for Dupilumab - GuruFocus
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Regeneron’s Drug Combo Fails To Prove Superiority Over Merck’s Keytruda In Melanoma - Stocktwits
Regeneron Pharmaceuticals (REGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Regeneron stock holds firm as the focus shifts to the pipeline - Ad-hoc-news.de
Did Disappointing Trial Data Amid Strong Dupixent and Eylea Sales Just Shift Regeneron’s (REGN) Investment Narrative? - simplywall.st
Own Regeneron For Biotech Growth? Incyte Is Making Its Case. - Trefis
Disappointing Trial Results Hurt Regeneron Pharmaceuticals (REGN) in Q2 - Yahoo Finance
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $730 - Moomoo
Cantor Fitzgerald reiterates Overweight on Regeneron stock - Investing.com
BofA Securities Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $856 - Moomoo
Regeneron Pharmaceuticals (REGN): Investor Outlook On Its 23.77% Potential Upside - DirectorsTalk Interviews
Regeneron Cites Medtronic Ruling In Amgen Bundling Case - Law360
REGN Maintained by Piper Sandler -- Price Target Lowered to $854 - GuruFocus
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $854 - Moomoo
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $854 From $855 - Moomoo
REGN Maintained by Morgan Stanley -- Price Target Lowered to $73 - GuruFocus
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
리제네론 파마슈티컬스 (REGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.96%
자본화:
|
볼륨(24시간):